Saturday, October 24, 2026

I went through all 142 companies in Value Line this morning. Here are the 6 that made it

Six Value Line small caps including Blackbaud, Marqeta, Ranger Energy and Definitive Healthcare trade on net cash, buybacks, low multiples or a takeover bid.

RNGR $344M

Calvin Blissett Oct 24 79 clicks

Oct 23 EROC $444M

Research & Analysis: ERock, Inc. (NYSE: EROC)

Monte Independent Investment Research 9 clicks

Oct 21 BMBL $787M

Bumble is being taken private

Modern Value Investing 8 clicks

From X

@majgeoinvesting Aug 10

Maj Soueidan on X

$MPAA - Dud Q1, but reaffirmed guidance. Most interested in seeing how long it will take to realize benefits from comp bankruptcy. The call might give clues. I’m still on the fence given mgmt. spotty track record. Worth noting that they’re buying stock. https://t.co/JYNccc6yM5 https://t.co/mwNrHQkxkT

@stockgutter Aug 10 1 click

SG on X

$JRSH reports record sales, some margin compression. Overall positive imo. https://t.co/VeHMq7Lo7F https://t.co/hqRrqoGRaP

@majgeoinvesting Aug 9

Maj Soueidan on X

~50 microcap earnings calls tomorrow. I'm most interested in: $HQI: Tough industry & EPS estimates are eh, but big share buyback in place & last call hinted the industry is bottoming. $MPAA: Propensity for missing guidance, but comp went bankrupt. Source: @InfoArbMonitor https://t.co/75Ia9CQzSh

@majgeoinvesting Aug 8

Maj Soueidan on X

Expanding on the subject of Tom Patton’s CEO track-record at medical device companies. It’s absolutely🔥. Would have been interesting to see what he could’ve done at $KRMD had he been the first CEO to replace the founder during the Board battle - or at least joined the board. https://t.co/1nwW0XeFOQ https://t.co/SdrnV5f7HY

@majgeoinvesting Aug 8 1 click

Maj Soueidan on X

Linda actually just bought a little not too long ago. So, not sure she’s a seller anytime soon. But, I need to be honest. I really liked Linda. I viewed her as one of those high quality CEOs you rarely see at the microcap level. I’m surprised/saddened she’s moved on from $KRMD, although she’s exiting at the top of some of her accomplishments at the company. •Pharma partner platform •Product innovation (high volume infusion, pre-filled syringes) •Reaching profitability, although minor. This is where I was hoping to see better traction (been a while since i looked, but not sure if they hit original timeline on gross margin target). All and all, KRMD is a recurring revenue machine. I’m surprised no one has bought them yet. The new CEO looks legit, but I would have loved to have seen Thomas Patton involved in the company, at least at the Board level. He never seemed interested whenever I brought it up - when the founder and Board were battling. So much of what he has touched has turned into home runs and in exits… Although $ECOR didn’t quite workout, but to be fair, he was only on the Board. His CEO record is impeccable. @ipo_candy @MoneyMarkStocks @neilcataldi - Tom should be your next call.

@stockgutter Aug 7 1 click

SG on X

$SB #sugar what a day! https://t.co/kWAiFObTRd https://t.co/zeODI0xbe5

@stockgutter Aug 7

SG on X

have to admit I did not think $NRGV would ever reach this level of revenue https://t.co/QSPwlU6M3e

@stockgutter Aug 7 1 click

SG on X

Market didn't like $MKTW report--shares are down 5%. I thought it was fine, especially the raise in guidance. Tell me why this business won't thrive over time? https://t.co/AOPkGU3D5Y

Unicycive (UNCY):

Unicycive’s oxylanthanum carbonate NDA earned a March 25, 2027 PDUFA date after two manufacturing-related rejections, with no FDA clinical…

UNCY $98M

Triple S Special Situations Investing Oct 22 4 clicks

GLOO, part two

Gloo faces related-party deals, insider-heavy IPO ownership, acquisition losses and $84.5 million of CEO-backed puts as it burns cash and…

GLOO $269M

Guardian Research Oct 21 4 clicks

Carecloud News

CareCloud may attract a private-equity buyer after its Q3 call, with acquiring enough shares the main obstacle to a take-private deal.

CCLD $74M

Calvin Blissett Oct 20 11 clicks

AGI Inc: The Bargain Is Even More Attractive

AGI Inc trades at 5.6x earnings after a 35% post-IPO decline, despite roughly 30% ROE and resilient INSS payroll-loan growth.

AGBK $790M

Multiplo Invest Oct 20 14 clicks

LXS.DE: a 2028 sale it can force

Lanxess can force Advent to buy at least half its Envalior stake in April 2028, potentially raising about €745 million to reduce net debt.

LPTH $578M

Trade Ideas Flow Oct 19 21 clicks

Sell Eagle Point Credit Now - Match The Loss With Portfolio Gains To Lower Income Taxes

Eagle Point Credit's NAV is down 25% YTD and shares nearly 50%, while its expense ratio climbed to 9.21% despite a 25% yield.

ECC $350M

Anthony Cataldo Oct 19 5 clicks

Build-A-Bear: A Narrower Path

Build-A-Bear's push into prestuffed toys and broader retail distribution tests brand stretchability, but recent results warrant caution.

BBW $292M

TSOH Investment Research Oct 19 18 clicks

LendingTree (NASDAQ: $TREE) – A Cyclical Comeback Story Priced as if the Cycle Never Turns

LendingTree derives roughly two-thirds of revenue from insurance and trades near 4 times expected adjusted earnings despite record revenue,…

TREE $362M

Substack von Philipp Oct 19 11 clicks

First Financial: Acquisitions Drive 2027 Growth

First Financial’s merger with First Illinois Financial is expected to lift net interest income and ROE from 2027 after Q2 net income rose…

THFF $937M

Sorrento Research Oct 18 2 clicks

GLOO: Gloo's own filings make the short case

Gloo's $3.25 follow-on, going-concern warning and $28.0 million first-half cash burn frame the short case against its acquisition-driven…

GLOO $269M

Guardian Research Oct 16 18 clicks

PYPD · long

Polypid LTD

PolyPid, an $80 million Israeli biotech, fell nearly 30% despite solving a clinical problem.

PYPD $106M

Value Investors Club Jul 25

Sagimet Biosciences: The U.S. Acne Trial Is A Replication Exercise, Not A Discovery Bet

Sagimet Biosciences' denifanstat enters a fully funded U.S. acne registration trial after Phase 3 results, with SGMT trading below cash and…

SGMT $676M

Equity Eagle Oct 21 3 clicks

Twenty Years in the Dark

Tower Properties, $TPRP, went dark after a 2006 squeeze-out cut holders below 300, leaving a Kemper-controlled apartment and office…

TPRP $128M

Orphan REITs Oct 16 5 clicks

TSOH Weekly Roundup (10/16/2026)

Bumble agreed to a $1.3 billion take-private deal, while Netflix cut about 1,000 jobs and Meta discussed its Muse superintelligence models.

BMBL $787M

TSOH Investment Research Oct 16 12 clicks

Problems at Dream Finders Homes (DFH)

Dream Finders Homes’ controlling owner borrowed against DFH stock before the homebuilder agreed to finance an acquisition with costly…

DFH $933M

Hunterbrook Oct 15 15 clicks

Park Aerospace: The Q2'27 Sell-Off Misreads a Sole-Source Defense Supplier

Park Aerospace’s 11% Q2’27 sell-off overlooks sole-source PAC-3 rocket-motor materials and A320neo engine composites, with missile capacity…

PKE $582M

Monte Independent Investment Research Oct 15 14 clicks

flyExclusive: Sell Despite Strong Turnaround

FlyExclusive posted 22% Q2 revenue growth and a 20.4% gross margin, but negative free cash flow, net debt and preferred capital leave…

FLYX $63M

Dhierin Bechai Oct 15 1 click

Private Equity Prints Multibaggers With This Pattern. No One is Talking About It.

Shenandoah Telecommunications’ Glo Fiber buildout ends this year, and private infrastructure investors’ repeated fiber deals frame a…

SHEN $523M

Phynvesting Oct 14 22 clicks

SED Energy: The 40% Dividend. Signal or Noise?

SED Energy's proposed Ventura merger projects a 22% to 40% dividend yield, but idle tender barges, debt and repayments materially reduce…

SBDXF $528M

Cannibal Stocks Oct 13 8 clicks

Cabaletta Bio: 40% Sell-Off Creates An Opportunity Despite Cash Concerns

Cabaletta Bio's 40% sell-off leaves CABA below its $2.41 pipeline value ahead of pivotal rese-cel autoimmune data in 2027, despite dilution…

CABA $229M

Cypriot Invests Oct 13 2 clicks

Saturday, October 24, 2026

Maj Soueidan on X

SG on X

Maj Soueidan on X

Maj Soueidan on X

Maj Soueidan on X

SG on X

SG on X

SG on X

Investor Letters

Publications we follow

Newsletters 109

YouTube 4

Blogs 15

Seeking Alpha 62 of 256

X accounts we follow

Investor letters we follow

Sectors